Intercept Commits To Resubmitting NASH NDA, But Analysts See Conflicting Signs

 
• By Joseph Haas
  
Back view image of young businessman standing against business sketch
Analysts wonder if Intercept is de-emphasizing NASH to focus on PBC
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business